Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has noted the publication by PLOS ONE of a study led by Leeds University Academic Unit of Health Economics, supported by NIHR Leeds In Vitro Diagnostics Co-operative, and funded by The National Institute for Health Research’s SBRI Healthcare programme, which evaluated the cost-effectiveness of the EarlyCDT Lung blood test in combination with Computed Tomography, compared to CT surveillance alone in the diagnosis of lung cancer amongst patients with Indeterminate Pulmonary Nodules.
The results of the study demonstrate that at an example cost of £70 per test, the EarlyCDT Lung blood test will have a positive impact on the outcomes of those patients observed, and when used alongside CT surveillance, is a cost-effective approach to the management of patients with IPNs. The study calculates the ICER to be £2,417, substantially below the accepted £20,000 per QALY (“quality adjusted life year”) threshold set by NICE.
According to Cancer Research UK1., there are approximately 50,000 new cases of lung cancer every year, making lung cancer the third most common cancer in the UK. Furthermore, lung cancer is the most common cause of cancer deaths in the UK, with 5- and 10-year survival rates as low as 10% and 5%, respectively. This highlights the need to detect and correctly treat lung cancer as early as possible.
The online publication at PLOS ONE can be accessed here: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0237492
1. https://www.cancerresearchuk.org/about-cancer/lung-cancer
Adam M Hill, CEO of Oncimmune Holdings said: “We are very pleased with the results of this study, demonstrating the cost effectiveness of the EarlyCDT Lung blood test as an adjunct to the diagnostic management of IPNs. The Leeds University Academic Unit of Health Economics and NIHR Leeds MIC were excellent delivery partners for this project. This study has enabled the generation of further data for the EarlyCDT Lung blood test that supports its adoption in ongoing discussions with healthcare providers across the UK.”
